



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

Medicago Achieves Positive Preclinical Study Results for Proprietary H5N1 Influenza VLP Vaccine

Quebec City, Quebec, October 31, 2007 — Medicago Inc. (TSX-V: MDG) today announced that preclinical testing of its pandemic H5N1 Influenza Virus-Like Particles (“VLP”) vaccine has shown positive results. Medicago’s Influenza VLP vaccine triggered a strong protective immune response against the lethal H5N1 Indonesia strain currently in circulation.

“We are extremely pleased with the results from this study. Our VLP vaccine offers in our opinion a highly promising avenue and could play a vital role in the world’s response to a flu pandemic. We also believe our proprietary transient expression system will allow us to produce VLP vaccines faster and at lower cost than our competitors using cell culture techniques,” said Andy Sheldon President and Chief Executive Officer of Medicago. “By combining our VLPs and plant-based manufacturing system, we intend to position Medicago to significantly increase the speed of a public health response in the event of an outbreak. This is important as we continue our discussions with potential partners. We expect to initiate a lethal challenge study with our VLP vaccine in the coming weeks.”

“These studies represent an important step towards the production of a safe and efficacious pandemic vaccine. Our Influenza VLP vaccine demonstrated it can provide a protective antibody response at doses as low as 1µg,” said Dr. Louis Vezina, Medicago’s Chief Scientific Officer. “In addition, our ability to potentially deliver a vaccine in a short time frame could prove critical in meeting a surge in global demand in the midst of a pandemic crisis.”

The objective of Medicago’s preclinical studies was to determine the optimal dosage of its VLP vaccine. Intra muscular and intranasal delivery routes were investigated with and without an adjuvant. At the start of preclinical trial, mice were immunized with Medicago’s VLP with doses ranging from 1µg to 12µg. A booster immunization was administered after three weeks. Results showed that the administration of Medicago’s VLP vaccine stimulated a significant seroprotective immune response in all animals who received doses as low as 1µg. Preliminary results also showed a strong antibody response even in the absence of an adjuvant. Studies were performed in collaboration with Dr. Brian Ward from McGill University.

About Medicago Inc.

Medicago is a biotechnology company focused on the development, production and commercialization of protein-based vaccines and biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants. Medicago’s Proficia technology offers speed, flexibility and cost advantages that can greatly improve the accessibility of today’s emerging vaccines and biopharmaceuticals for both partners and patients.

Forward Looking Statements

This press release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

Contact Information

Medicago Inc.
Andy Sheldon
President and CEO
(418) 658-9393

The Equicom Group Inc.
Eric Bouchard
Investor Relations
(514) 844-7997
ebouchard@equicomgroup.com